Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disoproxil fumarate

This page shows the latest tenofovir disoproxil fumarate news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... fumarate and emtricitabine – two

Latest news

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

  • ViiV takes two-drug cocktail for first-line HIV into phase III ViiV takes two-drug cocktail for first-line HIV into phase III

    three-drug regimen based on Tivicay and Gilead Sciences' double NRTI drug Truvada (tenofovir disoproxil fumarate/emtricitabine). ... HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    Gilead Sciences has added to its portfolio of HIV drugs in Europe after getting EMA approval for Odefsey, a three-drug combination based on its new tenofovir alafenamide (TAF) drug. ... It is a follow up to Gilead's $1.4bn Complera, which contains

  • Gilead bags EU approval for next-generation HIV drug Gilead bags EU approval for next-generation HIV drug

    Called Descovy, the drug is a new version of Gilead's $3.5bn-a-year Truvada (emtricitabine and tenofovir disoproxil fumarate or TDF) that replaces the TDF component with a new ... salt called tenofovir alafenamide (TAF).

More from news
Approximately 2 fully matching, plus 35 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics